# SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

> **NCT01385956** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 20 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** SOM 230 LAR
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01385956
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2014-05
- **Final completion:** 2014-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01385956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01385956, "SOM 230 and Gemcitabine in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01385956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*